Compare Ares Capital Corporation (ARCC) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Danaher Corporation — how do they compare? Ares Capital Corporation trades at $19.95 (market cap $14.35B), while Danaher Corporation trades at $207.4 (market cap $147.18B). The key difference: Danaher Corporation is far larger — about 10.3× Ares Capital Corporation's market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.
| ARCC | DHR | |
|---|---|---|
Market Cap | $14.35B | $147.18B |
Sector | Financials | Health |
52-Week High | $22.68 | $242.05 |
52-Week Low | $17.45 | $161.91 |
Dividend Yield | 9.61% | 0.76% |
Enterprise Value | — | $169.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $20.01, up 1.99% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show Q2 2026 EPS of $0.47, slightly below the $0.4731 estimate, continuing a trend of minor misses. Revenue declined to $1.51B in 2025 from $1.7B in 2024, with net income margin at 81.77%. The stock offers a high dividend yield, with consistent payouts highlighted in recent news.
Outlook is mixed: strong analyst buy consensus (75%) and a stable dividend history support income investors, but declining revenue and tight dividend coverage pose risks. Price target consensus is $19.63, below the current price, suggesting limited upside. Macro risks in private credit, per WSJ on August 9, 2026, add caution.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
